A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors

Clinical trial NCT01543698 · COMPLETED

Trial details

NCT number: NCT01543698
Sponsor: Pfizer
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Solid Tumors Harboring a BRAF V600 Mutation

Start date: 2012-05-28
Primary completion: 2023-03-09
Enrollment: 189

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.